kidney failure patients
Baxter (BAX): Bank on blood products
“Baxter International (NYSE: BAX) benefits from a robust balance sheet, solid operating momentum, and rising earnings estimates,” says Richard Moroney.
In Dow Theory Forecasts, he explains, “The first company to commercially prepare intravenous treatments, Baxter has manufactured and distributed medical products since 1931.” Here’s his bullish review of the stock.
“The first company to commercially prepare intravenous treatments, Baxter [...]
Search
Latest Headlines
- 10 Ways Electronic Breaches Could Blindside Global FinanceFrom hacking to coding mistakes and rogue insiders, the financial system is vulnerable to disruption […]
- Street Sways On Jobs DataU.S. equities off earlier lows, pressured by weekly jobless claims and narrowed trade deficit. […]
- How To Keep Your Employees Focused And Functioning, Even NowHere are three big steps you can take that cost nothing. […]
- New Zealand's 2009 WinesThe latest releases offer more of the same: Great value, with plenty of question marks --but all wor […]
- The Importance of Doing Meaningful WorkBusiness students often see little overlap between the jobs they plan to do and those they consider most socially responsible or would most enjoy. […]
New Stocks Live provides the latest stock news.
